文献速递贫血与红细胞疾病

单剂静脉铁剂FDI治疗妊娠期缺铁性贫血的疗效

Efficacy of Single-Dose Intravenous Ferric Derisomaltose for Iron Deficiency Anemia in Pregnancy.
PubMed 文献 · Am J Hematol · 2026-01-02

这项前瞻性单臂干预试验评估了单次1000 mg静脉铁剂FDI治疗妊娠中晚期缺铁性贫血的安全性和疗效。75例接受治疗者从基线至分娩平均血红蛋白升高1.3 g/dL,铁蛋白和转铁蛋白饱和度显著改善至产后6周,疲劳和抑郁评分亦改善,无严重输注反应。

要点

  • 单次1000 mg FDI可使妊娠期IDA患者血红蛋白平均升高1.3 g/dL。
  • 铁蛋白和转铁蛋白饱和度显著改善至产后6周,疲劳和抑郁评分改善。
  • 无严重输注反应,轻微症状多自限,仅2.6%未完成输注。

核心结论

  • 单次1000 mg静脉FDI是妊娠晚期缺铁性贫血安全有效的治疗选择。
  • 需在更大规模对照试验中进一步验证。

研究设计与样本

  • 前瞻性单臂干预试验,2024年1月至2025年7月纳入妊娠中晚期IDA患者78例,75例接受FDI。

主要发现

  • 从基线至分娩,平均血红蛋白升高1.3 g/dL。
  • 铁蛋白和转铁蛋白饱和度显著改善至产后6周(p < 0.001)。
  • 疲劳评分(p < 0.001)和爱丁堡产后抑郁量表评分(p = 0.003)改善。
  • 平均输注时间24分钟,脐血铁蛋白和血红蛋白提示新生儿铁状态改善。
  • 无严重输注反应或住院;轻微症状包括胸闷6.7%、潮红5.3%、轻度气短4%、荨麻疹2.7%、皮疹1.3%,2.6%未完成输注。

临床怎么用

  • 可考虑单次1000 mg静脉FDI用于妊娠中晚期缺铁性贫血,尤其口服铁不耐受或依从性差者。
  • 输注时间约24分钟,需监测轻微输注反应。

局限性

  • 单臂设计,无对照组,样本量有限(75例接受治疗)。
  • 需更大规模对照试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Iron deficiency anemia (IDA) is prevalent in pregnancy, yet oral iron therapies are associated with poor adherence and many intravenous (IV) iron formulations require multiple doses for treatment. Ferric derisomaltose (FDI) is a newer IV iron formulation that is safe and efficacious in non-pregnant individuals, yet pregnancy data is lacking. We evaluated the safety, efficacy, and maternal and neonatal outcomes associated with a single 1000 mg IV dose of FDI in pregnant individuals with IDA. We conducted a prospective, single-arm interventional trial of FDI administered in the second or third trimester of pregnancy from January 2024 to July 2025. The primary outcome was efficacy (hemoglobin increase of ≥ 1 g/dL). Secondary outcomes included safety, other hematologic parameters, patient-reported quality of life, and maternal and neonatal outcomes. Among 78 participants enrolled, 75 received FDI. From baseline to delivery, mean hemoglobin increased by 1.3 g/dL, with significant improvements (p < 0.001) in ferritin and transferrin saturation through 6 weeks postpartum. Patient-reported fatigue scores improved (p < 0.001), as did Edinburgh Postnatal Depression Scale scores (p = 0.003). The mean FDI infusion time was 24 min. Cord blood ferritin and hemoglobin values suggested enhanced neonatal iron status. No major infusion reactions or hospitalizations occurred. Minor infusion-related symptoms were uncommon and self-limited: chest tightness (6.7%), flushing (5.3%), mild shortness of breath (4%), urticaria (2.7%), rash (1.3%). Two patients (2.6%) did not complete the infusion due to reaction. These findings support single-dose IV FDI as a safe and effective option for late-pregnancy IDA, meriting further evaluation in larger controlled trials.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Benson AE, Martens KL, Rincon M, et al. Efficacy of Single-Dose Intravenous Ferric Derisomaltose for Iron Deficiency Anemia in Pregnancy. Am J Hematol. 2026. PMID: 41479368. doi:10.1002/ajh.70190

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。